Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Grows By 36.8%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a significant increase in short interest in February. As of February 28th, there was short interest totalling 53,900 shares, an increase of 36.8% from the February 13th total of 39,400 shares. Based on an average trading volume of 100 shares, the short-interest ratio is presently 539.0 days. Approximately 0.0% of the company’s shares are sold short.

Inhibitor Therapeutics Price Performance

Shares of Inhibitor Therapeutics stock remained flat at $0.07 during trading on Friday. 13,727 shares of the company traded hands, compared to its average volume of 38,647. The firm has a market capitalization of $12.06 million, a P/E ratio of -7.00 and a beta of -0.55. The business’s 50 day moving average price is $0.06 and its two-hundred day moving average price is $0.07. Inhibitor Therapeutics has a 52 week low of $0.04 and a 52 week high of $0.14.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.